WALTHAM, Mass., Nov. 13, 2012 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (BGMD), a company focused on the development and commercialization of novel cardiovascular diagnostics, today provided an update on its new commercial strategy to speed the adoption of its cardiovascular diagnostic tests -- the BGM Galectin-3^(R) test and the CardioSCORE^TM test.

WALTHAM, Mass., Nov 9, 2012 (GlobeNewswire via COMTEX) -- BG Medicine Inc., a company focused on the development and commercialization of novel cardiovascular diagnostics, today announced that results of retrospective analyses of the BioImage Study cohort were presented this week at the American Heart Association (AHA) Scientific Sessions 2012 in Los Angeles. These presentations resulted from research sponsored by the company and included data on the CardioSCORE(TM) test, a proprietary blood test currently being developed by the company.

New investors join existing investors to expand Series A with $13M in new funding

BURLINGTON, MA, November 5, 2012 – Black Duck, the trusted partner for open source software adoption, management and governance, has been named a Top Place to Work in Massachusetts in the 2012 employee-based survey from The Boston Globe.

WALTHAM, Mass.

Collaboration to deploy Ensemble's innovative platform to discover small molecule drug candidates for Boehringer Ingelheim's targets

CAMBRIDGE, Mass., Nov 01, 2012 (BUSINESS WIRE) -- Ensemble Therapeutics today announced the initiation of a research collaboration with Boehringer Ingelheim to discover drug candidates of a novel class of small molecule drugs, called macrocycles, against several high-value pharmaceutical targets specified by Boehringer Ingelheim.

Avedro to hold exclusive license to broad iontophoresis patent portfolio

(GLOBE NEWSWIRE) -- LS9, Inc., a technology leader in the development of renewable and sustainable chemicals and fuels, today announced that the The Wall Street Journal selected the Company as one of the 2012 Top 10 Venture-Backed Green Companies.

WALTHAM, Mass., Oct. 18, 2012 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a company focused on the development and commercialization of novel cardiovascular diagnostics, announced today that it has appointed Charles H. Abdalian, Jr., as the company's Executive Vice President, Chief Financial Officer. Mr.